Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Immunomedics Inc (NASDAQ:IMMU)

12.41
Delayed Data
As of Dec 14
 +0.18 / +1.47%
Today’s Change
3.30
Today|||52-Week Range
14.48
+238.15%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$1.9B

Company Description

Immunomedics, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of researching, developing, manufacturing and marketing biopharmaceutical products. The company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. It markets and sells its products in the U.S. and throughout Europe. The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.

Contact Information

Immunomedics, Inc.
300 The American Road
Morris Plains New Jersey 07950
P:(973) 605-8200
Investor Relations:
19736058200123

Employees

Shareholders

Other institutional55.00%
Mutual fund holders19.96%
Individual stakeholders15.12%

Top Executives

Michael PehlChief Executive Officer-Designee
Michael R. GaroneChief Financial Officer & Vice President
William A. WegenerChief Medical Officer
Brendan DelaneyChief Commercial Officer
Chau ChengSecretary & Senior Director-Investor Relations